Coya Therapeutics (NASDAQ:COYA) Stock Dropped to “Strong Sell” by Wall Street Zen

Wall Street Zen lowered shares of Coya Therapeutics (NASDAQ:COYA) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Thursday. BTIG Research reissued a “buy” rating and set a $16.00 price target on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Finally, Roth Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a report on Monday, August 24th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Coya Therapeutics Trading Down 4.3%

Shares of Coya Therapeutics stock traded down $0.14 during trading on Friday, reaching $3.13. The company’s stock had a trading volume of 189,167 shares, compared to its average volume of 174,773. The stock has a 50-day moving average price of $4.29 and a two-hundred day moving average price of $4.58. Coya Therapeutics has a one year low of $2.72 and a one year high of $6.62. The stock has a market capitalization of $73.43 million, a P/E ratio of -2.25 and a beta of 0.70.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.11). Coya Therapeutics had a negative return on equity of 71.48% and a negative net margin of 643.44%. The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.11 million. As a group, sell-side analysts anticipate that Coya Therapeutics will post -1.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of COYA. Marshall Wace LLP raised its position in shares of Coya Therapeutics by 29.6% during the 3rd quarter. Marshall Wace LLP now owns 323,849 shares of the company’s stock valued at $1,622,000 after acquiring an additional 74,056 shares during the last quarter. Allworth Financial LP raised its holdings in Coya Therapeutics by 1,200.0% in the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock worth $76,000 after purchasing an additional 12,000 shares during the period. AXQ Capital LP bought a new position in shares of Coya Therapeutics during the second quarter worth $116,000. Long Corridor Asset Management Ltd bought a new position in shares of Coya Therapeutics during the second quarter worth $227,000. Finally, Renaissance Technologies LLC boosted its position in shares of Coya Therapeutics by 55.4% during the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after purchasing an additional 37,064 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.